Skip to content
Screener

Gilead Sciences GILD Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$7.0BBeat by $46.6M
EPS$2.03Beat by $0.12
Revenue estimate$6.9B
EPS estimate$1.91
“Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance, Building on the strongest pipeline in Gilead’s history, we are adding potentially best-in-disease assets and platforms in oncology and inflammation from our acquisitions of Arcellx, Ouro Medicines and Tubulis. With up to four potential launches and five Phase 3 updates anticipated in 2026, Gilead is well-positioned for sustained growth in the near and long term.”
Daniel O’Day

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$7.8B
EPS estimate$2.12

Financials

Q1 2026

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$172.99B+23.8%
Enterprise value$187.53B+19.7%
P/E18.8×-4.6×
P/S5.8×+1.0×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Segments

By product

See full
Biktarvy$3.4B+6.7%
Descovy$807.0M+37.7%
Trodelvy$402.0M+37.2%
Yescarta$332.0M-14.0%
Sofosbuvir/Velpatasvir$283.0M-18.2%

By geography

See full
Europe$1.1B+5.5%
Rest of World$889.0M-2.8%

FAQ

When did Gilead Sciences report Q1 2026 earnings?
Gilead Sciences (GILD) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Gilead Sciences's Q1 2026 revenue and EPS?
Gilead Sciences reported revenue of $7.0B and eps of $2.03 for Q1 2026.
Did Gilead Sciences beat estimates in Q1 2026?
Revenue beat the consensus estimate of $6.9B by $46.6M. EPS beat the consensus estimate of $1.91 by $0.12.
How did Gilead Sciences's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.4% from $6.7B a year earlier and eps grew 12.2% from $1.81.
Where can I find Gilead Sciences's Q1 2026 SEC filings?
You can read the 8-K earnings release (0000882095-26-000008) and the 10-Q periodic report (0000882095-26-000024) directly on SEC EDGAR. The filing index links above go to sec.gov.